In this first study directly comparing two SGLT2 inhibitors with allopurinol regarding their impact on sUA and eGFR over a 36-month follow-up period, our analyses confirm the significant urate-lowering effect of SGLT2 inhibitors and highlight their potential benefits in the management of HUA in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.